COMPENDIUM Analysis Group Health Economics, Outcomes & Epidemiology PUBLISHED RESEARCH AND PRESENTATIONS COMPENDIUM Analysis Group Health Economics, Outcomes & Epidemiology PUBLISHED RESEARCH AND PRESENTATIONS A COMPENDIUM OF OUR RESEARCH Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoeconomics in place for ready use across their customers and therapeutic areas. For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through May 2018. For more information on our research activities and health care consulting practice, please visit our website, www.analysisgroup.com. CONFIDENTIAL COMPENDIUM Analysis Group CONTENTS Autoimmune/Inflammatory 4 Cardiovascular 19 Dermatology 40 Endocrine/Metabolic/Diabetes 54 Gastrointestinal 70 Hematology 83 Infectious Diseases 98 Neurology 105 Oncology 141 Renal 200 Respiratory 205 Substance Abuse 216 Other Diseases & Conditions 220 Other (Health Policy, Market Access, and other topics) 231 Analysis Group COMPENDIUM Autoimmune/Inflammatory Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. Publication: Journal of Medical Economics 2018 05: 1-7 Authors: Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Publication: Current Medical Research and Opinion 2018 05: 1-9 Authors: Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW. Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis. Publication: Journal of Managed Care and Specialty Pharmacy 2018 04; 24(4): 344-352 Authors: Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M. Burden of illness of systemic sclerosis among commercially insured patients. Abstract: Steering Committee of the 5th Systemic Sclerosis World Congress, Bordeaux, France. Authors: Zhou Z, Yu Y, Tang W, Liu W, Thomason D, Zhou Z, Macaulay D, Fischer A. Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients. San Diego, California. Authors: Zhou Z, Yu Y, Liu W, Tang W, Zhou Z, Thomason D, Macaulay D, Fischer A. Burden of Work Instability in Patients with Rheumatoid Arthritis in US and Its Association with Work Productivity and Transitions. Abstract: Academy of Managed Care & Specialty Pharmacy Annual Meeting, Boston, MA. Authors: Tundia N, Zhou J, Yang M, Macaulay D, JR C. Economic burden of illness among commercially-insured patients with systemic sclerosis in the United States. Abstract: Systemic Sclerosis World Congress, 5th Annual, Bordeaux, France. Authors: Zhou Z, Yu Y, Tang W, Liu X, Thomason D, Zhou Z, Macaulay D, Fischer A. Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD). Boston, MA. Authors: Thomason D, Yu Y, Zhou Z, Tang W, Liu X, Zhou Z, Macaulay D, Fischer A. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world. Publication: Clinical and Experimental Rheumatology 2017 03; 35(5): 791-798 Authors: Yang M, Galebach PJ, Signorovitch JE, Garg V. Economic burden of sarcoidosis in a commercially-insured population in the United States. Publication: Journal of Medical Economics 2017 10; 20(10): 1048-1055 Authors: Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Publication: Clinical Therapeutics 2017 11; 39(11): 2216-2229 Authors: Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. PAGE 4 COMPENDIUM Analysis Group HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data. Abstract: Annual European Congress of Rheumatology, Madrid, Spain. Authors: Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Publication: Rheumatology International 2017 06: 1-12 Authors: Husni ME, Betts KA, Griffith J, Song Y, Ganguli A. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. Publication: Rheumatology Therapeutics 2017 07; Authors: Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population. Publication: Journal of Medical Economics 2017 12; 20(12): 1299-1306 Authors: Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Publication: Clinical Therapeutics 2017 08; 39(8): 1618-1627 Authors: Li N, Betts KA, Messali AJ, Skup M, Garg V. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Publication: Clinical Therapeutics 2017 07; 39(8): 1680-1694 e1682 Authors: Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. Publication: Clinical Therapeutics 2017 03; 39(4): 849-862 e846 Authors: Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M. Association of corticosteroid exposure with ophthalmologic complications and systemic adverse events in non-infectious uveitis patients using administrative claims in the United States. Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, San Diego, CA. Authors: Acharya N, Betts KA, Patterson-Lomba O, Ganguli A, Schonfeld S, Griffith J. Quantifying clinical and economic outcomes associated with chronic corticosteroid exposure in a US population. Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, San Diego, CA. Authors: Rice JB, White A, Lopez A, Wagh A, Qin Y, Mitri G, Bartels-Peculis L, Ciepielewska G, Nelson W. Burden of high disease activity in systemic lupus erythematosus (SLE): Results of a targeted literature review. Abstract: ISPOR 20th Annual European Congress, Glasgow, United Kingdom. Authors: Tan R, Adamski K, Tuttle E, Guenther O, Henke C. PAGE 5 Analysis Group COMPENDIUM Network meta-analysis of targeted immunomodulators in the treatment of biologic-naive psoriatic arthritis. Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. Authors: Strand V, Husni ME, Singh R, Betts K, Song Y, Griffith J, Ganguli A. Association between disease activity level improvement and reduction in healthcare resource utilization in patients with rheumatoid arthritis receiving targeted therapy. Abstract: ISPOR 22nd Annual International Meeting. Authors: Lopez A, Priest J, Duh MS, McDonnell E, Bobbili PJ, Haider BA, Sundaresan D, Yood RA, Reed JI. Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis. Abstract: American Academy of Dermatology 75th Annual Meeting, Orlando, FL. Authors: Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G. High-cost sarcoidosis patients in the United States: Patient characteristics and patterns of health care resource utilization. Publication: Journal of Managed Care and Specialty Pharmacy 2017 12; 23(12): 1261-1269a Authors: Rice JB, White A, Lopez A, Nelson WW. Economic Evaluation of Timely versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. Publication: Rheumatology Therapeutics 2016 09; Authors: Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Publication: Clinical Therapeutics 2016 05; 38(5): 1205-1216 Authors: Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Publication: Advances in Therapy 2016 05; 33(5): 807-823 Authors: Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A. Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha